469 Studies Now Enrolling
A Phase 3, Randomized, Double-Blind, Placebo - and Active - Comparator - Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma
| Sponsor: | Merck |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU7433 |
| U.S. Govt. ID: | NCT05933577 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not been approved for use with V940.
